TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet Form
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background. Recent guidelines from the American Thyroid Association (ATA) indicate that, in many patients affected by differentiated thyroid cancer (DTC), the serum TSH should be maintained between 0.1 and 0.5 mU/L. The purpose of this study was to evaluate the TSH variability of patients affected by DTC treated with liquid L-T4 formulation or in tablet form. Patients and Methods. Patients were eligible if (a) they were submitted to a total thyroidectomy and 131 I remnant ablation for DTC in our institution and (b) they were classified low-risk patients according to ATA guidelines 2009. Patients were randomized (1 : 1) to receive treatment of hypothyroidism with liquid L-T4 or tablet form. The first check-up evaluation was made from 8 to 12 months after 131 I remnant ablation. TSH values were established again after further 12 months. Results. A significant increase in TSH values (median) was observed in patients taking tablets [TSH (min–max): 0.28 (0.1–0.45) versus 0.34 (0.01–0.78) mIU/L, p=0.041] as compared to those taking liquid formulation [TSH (min–max): 0.28 (0.1–0.47) versus 0.30 (0.1–0.55) mIU/L, p=0.345]. Conclusions. The use of L-T4 liquid formulation, as compared to that of tablets, resulted in a significantly higher number of DTC patients maintaining TSH values in range for the ATA risk score, reducing TSH variability over the time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686 · cited 1×
“reported large variations among individuals and thus a low index of individuality for thyroid function tests [4, 5].”
BackgroundThyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 1×
“have in fact demonstrated that patients with impaired acid secretion require an increased dose of thyroxine, confirming that normal acid gastric secretion is necessary for the effective absorption of oral L-T4 [25].”
BackgroundBiondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286 · cited 1×
“with L-T4 contribute to achieving this objective and to improving quality of life [19, 20].”
BackgroundLean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases
Santini, F., Pinchera, A., Marsili, A., Ceccarini, G., Castagna, M. G., Valeriano, R., Giannetti, M., Taddei, D., Centoni, R., Scartabelli, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1306 · Cited by 226 · cited 1×
“0mcg/kg/day), changing with the increase or decrease in the body weight itself [33].”
BackgroundConditions and drugs interfering with thyroxine absorption
Liwanpo, L., & Hershman, J. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.006 · Cited by 222 · cited 1×
“In order to avoid any possible confounding variables, patients taking any medications known to interfere with L-T4 absorption [14] were excluded from the study.”
BackgroundVadiveloo, T., Donnan, P. T., Cochrane, L., & Leese, G. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2693 · Cited by 186
Klein Hesselink, E. N., Klein Hesselink, M. S., de Bock, G. H., Gansevoort, R. T., Bakker, S. J. L., Vredeveld, E. J., van der Horst-Schrivers, A. N. A., van der Horst, I. C. C., Kamphuisen, P. W., Plukker, J. T. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1043 · Cited by 183 · cited 1×
“have, in fact, shown that, in patients affected by DTC, a lower TSH level is associated with increased cardiovascular mortality, independent of age, sex, and cardiovascular risk factors, more than the DTC itself [21].”
BackgroundVita, R., Saraceno, G., Trimarchi, F., & Benvenga, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2684 · Cited by 99
Fallahi, P., Ferrari, S. M., Camastra, S., Politti, U., Ruffilli, I., Vita, R., Navarra, G., Benvenga, S., & Antonelli, A. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2247-4 · Cited by 81
Cappelli, C., Pirola, I., Daffini, L., Formenti, A., Iacobello, C., Cristiano, A., Gandossi, E., Agabiti Rosei, E., & Castellano, M. (2016) · Thyroid · doi:10.1089/thy.2015.0422 · Cited by 80
Self-citationPirola, I., Formenti, A. M., Gandossi, E., Mittempergher, F., Casella, C., Agosti, B., & Cappelli, C. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1015-y · Cited by 74
Self-citationFallahi, P., Ferrari, S. M., & Antonelli, A. (2016) · Endocrine · doi:10.1007/s12020-015-0836-y · Cited by 53 · cited 1×
“We show that liquid L-T4 ismore effective than L-T4 tablet in controlling TSH levels in hypothyroid patients without malabsorption, gastric disorders, or drug interference [12].”
BackgroundPirola, I., Daffini, L., Gandossi, E., Lombardi, D., Formenti, A., Castellano, M., & Cappelli, C. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0082-9 · Cited by 47
Fallahi, P., Ferrari, S. M., Ruffilli, I., & Antonelli, A. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0439-y · Cited by 46
Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients
Negro, R., Valcavi, R., Agrimi, D., & Toulis, K. A. (2014) · Endocrine Practice · doi:10.4158/ep13378.or · Cited by 36 · cited 1×
“reported interesting data in this respect, showing that the administration of a liquid L-T4 formulation compared to tablets resulted in a significantly higher number of hypothyroid patients who remained euthyroid at the 12-month check-up, with a significant reduction of variability in TSH values [10].”
Tanguay, M., Girard, J., Scarsi, C., Mautone, G., & Larouche, R. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.608 · Cited by 33
Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation
Morelli, S., Reboldi, G., Moretti, S., Menicali, E., Avenia, N., & Puxeddu, E. (2016) · Endocrine · doi:10.1007/s12020-015-0788-2 · Cited by 30
Cited by
Castellana, M., Castellana, C., Giovanella, L., & Trimboli, P. (2020) · Endocrine · doi:10.1007/s12020-019-02185-4 · Cited by 41
“In patients treated for DTC, the use of LS LT4 formulation was associated with a better control and lower TSH variability compared with tablets [63, 64].”
BackgroundLevothyroxine therapy in thyrodectomized patients
Miccoli, P., Materazzi, G., & Rossi, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.626268 · Cited by 40
Tanguay, M., Girard, J., Scarsi, C., Mautone, G., & Larouche, R. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.608 · Cited by 33
Laurent, I., Tang, S., Astère, M., Wang, K. R., Deng, S., Xiao, L., & Li, Q. F. (2018) · Endocrine · doi:10.1007/s12020-018-1574-8 · Cited by 30
Bornikowska, K., Gietka-Czernel, M., Raczkiewicz, D., Glinicki, P., & Zgliczyński, W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225233 · Cited by 17
Metadata
- Authors
- Cappelli, C., Pirola, I., Gandossi, E., Casella, C., Lombardi, D., Agosti, B., Marini, F., Delbarba, A., & Castellano, M.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-5
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W2614086523
- Cited by
- 21
- References
- 18
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.